Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Post by theNormon May 08, 2020 10:02am
104 Views
Post# 31002487

Gaps, love it

Gaps, love it

Last: 0.405   Change: 0.010    Volume: 362,594   Last Trade: 09:57  

  Level ll Quote
  Bid     Ask
  Price   Total Size   # of Orders     Price   Total Size   # of Orders
$0.395 46000 5   $0.41 90000 7
$0.39 23500 6   $0.415 20000 1
$0.385 43000 9   $0.42 52000 3
$0.38 75500 11   $0.425 66500 5
$0.375 22000 5   $0.43 141500 5
$0.37 34500 7   $0.435 1000 1
$0.365 31000 3   $0.44 6500 2
$0.36 42000 7   $0.45 26500 2
$0.355 20000 2   $0.46 23500 2
$0.35 81500 15   $0.47 13500 3
Last: 0.405   Change: 0.010    Volume: 362,594   Last Trade: 09:57  

  Level ll Quote
  Bid     Ask
  Price   Total Size   # of Orders     Price   Total Size   # of Orders
$0.395 46000 5   $0.41 90000 7
$0.39 23500 6   $0.415 20000 1
$0.385 43000 9   $0.42 52000 3
$0.38 75500 11   $0.425 66500 5
$0.375 22000 5   $0.43 141500 5
$0.37 34500 7   $0.435 1000 1
$0.365 31000 3   $0.44 6500 2
$0.36 42000 7   $0.45 26500 2
$0.355 20000 2   $0.46 23500 2
$0.35 81500 15   $0.47 13500 3
 

Last: 0.405   Change: 0.010    Volume: 362,594   Last Trade: 09:57  

  Level ll Quote
  Bid     Ask
  Price   Total Size   # of Orders     Price   Total Size   # of Orders
$0.395 46000 5   $0.41 90000 7
$0.39 23500 6   $0.415 20000 1
$0.385 43000 9   $0.42 52000 3
$0.38 75500 11   $0.425 66500 5
$0.375 22000 5   $0.43 141500 5
$0.37 34500 7   $0.435 1000 1
$0.365 31000 3   $0.44 6500 2
$0.36 42000 7   $0.45 26500 2
$0.355 20000 2   $0.46 23500 2
$0.35 81500 15   $0.47 13500 3
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities